Abstract: In OLEDs, improved efficiency is obtained by using compounds of formula [Ar](CH?CH—R1)n wherein n is an integer from 1 to 4; [Ar] is a polycyclic aromatic or heteroaromatic scaffold optionally substituted with one or more alkyl or alkoxy groups; and R1 is a 5-membered heteroaryl group optionally substituted with methyl, methoxy, aryl or heteroaryl, or is phenyl or naphthyl optionally substituted with methyl, methoxy, trifluoromethyl or cyano or is biphenyl or substituted biphenyl. The compounds are believed to be novel and can be made by condensing a compound of formula wherein [Ar] and n are as defined above with a compound of formula [Ar](CH3)nR1CHO in the presence of an acid catalyst e.g. an anhydride of an organic acid.

Abstract: Use of an activated solid phase and a peptide-conjugated anchoring part for solid phase peptide synthesis, wherein the anchoring part is coordinatively and reversibly attached to the activated solid phase.

Abstract: Biheteroaryl metal complexes and the use thereof as bleach catalysts are described.

Abstract: An object of the invention is to provide an organic compound having excellent characteristics as a material for highly efficient and highly durable organic EL devices, and also to provide a highly efficient and highly durable organic EL device. This invention relates to a compound represented by the general formula (1) having an oxadiazole ring structure bonded with an aromatic heterocycle, and to an organic electroluminescence device containing the compound: wherein Ar represents a substituted or unsubstituted aromatic hydrocarbon group, a substituted or unsubstituted aromatic heterocyclic group, or a substituted or unsubstituted condensed polycyclic aromatic group; A represents a substituted or unsubstituted aromatic heterocyclic group; and n represents an integer of 1 to 3.

Abstract: Disclosed are electroluminescent devices that comprise organic layers that contain dibenzofuran compounds. The compounds are suitable components of, for example, blue-emitting, durable, organo-electroluminescent layers. The electroluminescent devices may be employed for full color display panels in, for example, mobile phones, televisions and personal computer screens.

Abstract: A novel phenanthroline compound is provided which is suitable as a compound for an organic EL device and is represented by the general formula (I): wherein R1, R2, R3, R4, R5, R6, R7, and R8 are each independently a hydrogen atom, an alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic group, or a halogen atom with the proviso that at least one of R1, R2, R3, R4, R5, R6, R7, and R8 is a group represented by the general formula (II): and R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, and R20 are each independently a hydrogen atom, an alkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic group, or a halogen atom.

Abstract: The present invention provides a novel electron transporting material having good heat resistance and being capable of forming devices with high thermal characteristics and an organic light-emitting device therewith. The phenanthroline derivative represented by the general formula below is used as the electron transporting material to form the organic light-emitting device: wherein the position of the substituent R6 or R7 depends on the position of the linkage between the phenanthrolinyl group and the fluorenyl group; X represents a single bond between the phenanthrolinyl group and the fluorenyl group; n0 and n1 each independently represent an integer of 0 to 2; and n2 and n3 each represent the number of the substituents and each independently represent an integer of 1 to 4.

Abstract: The present invention provides substituted phenanthroline compounds with high two photon absorption cross sections, as well as substituted phenanthroline compounds which additionally have quenched fluorescence emission upon two photon absorption.

Abstract: The present invention discloses a phenanthroline compound which can be used as electron-transporting material in organic electroluminescence devices is disclosed. The mentioned phenanthroline compound is represented by the following. wherein Ar is selected from the group consisting of hydrogen atom, alkyl, aryl, wherein R1, R2 and R3 are identical or different. R1, R2 and R3 are independently selected from the group consisting of hydrogen atom, alkyl, halide, wherein X1, X2 and X3 are identical or different. X1, X2 and X3 are independently selected from the atom or group consisting of O, S, N—R4 and R4 is selected from the group consisting of hydrogen atom, alkyl, aryl.

Abstract: There is provided an organic light-emitting device having an optical output with a high a high efficiency and a high luminance, and having good durability. The organic light-emitting device includes an anode, a cathode, and a layer including an organic compound interposed between the anode and the cathode, in which the layer contains a naphthalene compound represented by the general formula (1): wherein Ar1's each represent a substituted or unsubstituted fused ring aromatic hydrocarbon group having four or more rings.

Abstract: The present invention relates to fluorescent diketopyrrolopyrroles of the formula (I), or (III), a process for their preparation and their use for the preparation of inks, colorants, pigmented plastics for coatings, non-impact-printing material, color filters, cosmetics, polymeric ink particles, toners, as fluorescent tracers, in color changing media, in solid dye lasers, EL lasers and electroluminescent devices. A luminescent device comprising a compound, or composition according to the present invention is high in the efficiency of electrical energy utilisation and high in luminance.

Abstract: A bipyridine-based metal complex includes a complex of bipyridine-based ligands and metals, and is utilized in an ink composition. The bipyridine-based metal complex may be used alone, as well as in combination with other coloring agents.

Abstract: A novel azafluorene derivative and an organic light-emitting device having the derivative are provided. The organic light-emitting device includes a pair of electrodes composed of an anode and a cathode one of which is a transparent or semi-transparent electrode, and an organic compound layer interposed between the pair of electrodes.

Abstract: A compound having a diphenylanthracene structure at the center and a specific structure substituted with an aryl group at end portions. An organic electroluminescence device comprises a plurality of layers of thin films of organic compounds which comprise a light emitting layer or a plurality of layers comprising a light emitting layer and are disposed between a pair of electrodes and at least one of the layers of thin films of organic compounds comprises the above compound. The compound exhibits excellent efficiency of light emission and heat resistance, has a long life and emits bluish light having excellent purity of color and the organic electroluminescence device comprises the compound and exhibits the same advantageous properties.

Abstract: Diarylethene-containing ligands and their coordination compounds are described. The ligands display photochromism with UV excitation, while the coordination compounds display photochromism with both excitation in the UV region and excitation into lower energy absorption bands characteristic of the coordination compounds, through which the excitation wavelengths for the photocyclization can be extended from ??340 nm to wavelengths beyond 470 nm. Switching of the luminescence properties of the compounds has also been achieved through photochromic reactions.

Abstract: A platinum complex represented by the general formula (1) below, useful as a phosphorescence emission material, a tetradentate ligand useful for synthesizing the platinum complex, and a light-emitting device containing at least one of the platinum complex. wherein ring B represents a nitrogen-containing aromatic heterocyclic ring; rings A, C and D each independently represent an aromatic or aromatic heterocyclic ring, while either of the rings C and D represents five-membered ring, the other represents a five- or six-membered ring; RA, RB, RC, and RD respectively represent substituents on the rings A, B, C, and D; two of XA, XB, XC, and XD represent a nitrogen atom that may be bound with the platinum atom by a coordinate bond, the others each independently represent a carbon atom or nitrogen atom that may be bound with the platinum atom by a covalent bond; Q represents a bivalent atom or atomic group bridging the rings B and C; and YC and YD each independently represent a carbon atom or nitrogen atom.

Abstract: The present invention discloses a dipyridine-based compound which can be used as electron-transporting and/or hole blocking material or phosphorous host in organic electroluminescence devices is disclosed. The mentioned dipyridine-based compound is represented by the following formula: wherein R1 and R2 are identical or different, and R1 and R2 are independently selected from the group consisting of: hydrogen atom, aryl moiety, hetero cycle, multiple fused ring, multiple fused ring with hetero atom(s); A is selected from the following group: wherein R3 and R4 are identical or different, R5 and R6 are identical or different, R7 and R8 are identical or different, R3, R4, R7, R8 are independently selected from the group consisting of: alkyl moiety and aryl moiety, and R5, R6 are independently selected from the group consisting of: alkyl moiety, aryl moiety and arylamine moiety.

Abstract: This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.

Abstract: An organic light emitting device having a pyrene based electron transport compound and an electron injecting and transport layer comprising the electron transport compound is provided.

Abstract: The present invention relates to charge transport compositions. The invention further relates to electronic devices in which there is at least one active layer comprising such charge transport compositions.

Abstract: The invention provides methods for treating cancer and compounds that are useful for the treatment of tumors, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates useful for preparing the compounds.

Abstract: A novel bathophenanthroline compound of the general formula [I] or [II] is provided wherein R1 and R2 may be the same or different and independently represent a linear, branched or cyclic, saturated or unsaturated hydrocarbon group, or a substituted or unsubstituted, saturated or unsaturated hydrocarbon group provided that at least one of R1 and R2 has at least two carbon atoms, and wherein Ar1 and Ar2 may be the same or different and independently represent a substituted or unsubstituted aryl group. A process for preparing the compound is also provided wherein bathophenanthroline and an organolithium compound are subjected to nucleophilic substitution reaction to obtain the compound of the above formula [I] or [II].

Abstract: The present invention relates to charge transport compositions. The invention further relates to electronic devices in which there is at least one active layer comprising such charge transport compositions.

Abstract: Pyridoarylphenyl oxazolidinone compounds of the formula: in which the substituents have the meaning indicated in the description. These compounds are useful as antibacterial agents.

Abstract: Compounds of the formula (I), in which R1, R2, R3, R4 and R5 have the meanings indicated in the description, are novel effective PDE3/4 Inhibitors.

Abstract: The invention relates to cerium compounds having general formulas (I) Rni+Yin? and (II) Rb+Yb+ and their application as medicaments in the prophylaxis and/or treatment of cancer diseases.

Abstract: Bipyridine or phenanthroline ligands presenting functional groups that prevent non-specific binding (in particular, negatively charged functional groups that are unaffected by standard conditions for conjugating biological reagents through amide bonds) are described as are luminescent metal complexes comprising these ligands. The use of luminescent ruthenium and osmium complexes comprising these ligands in electrochemiluminescence assays shows that the use of these labels can significantly reduce the amount of non-specific binding observed relative to assays carried out using reagents labeled with analogous labels that don't present functional groups that decrease non-specific binding.

Abstract: The invention provides methods for treating cancer and compounds that are useful for the treatment of tumors, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates useful for preparing the compounds.

Abstract: Process for preparing 1,10-phenanthroline ligands represented by the formula which comprises coupling a 1,10-phenanthroline of the formula with a ketone e.g. a dialkyl, cycloalkyl or bicycloalkyl ketone with a metal coupling reagent, preferably a lanthanide II e.g. samarium II, wherein R is hydrogen, alkyl, cycloalkyl, bicycloalkyl or aryl e.g. phenyl. The hydroxy group of the product may be converted to derivatives e.g. esters and ethers to form additional ligands. The hydroxy group of the product also may be converted to a reducible group e.g. the methoxy ether and the ether replaced by hydrogen in the reduction. The reduction product wherein R of the starting material is hydrogen can be coupled with a ketone in the process to provide 2,9-disubstituted 1,10-phenanthroline ligands. The ligands provided are preferably in chiral form and complex with metals, e.g. transition metals, which serve as catalysts in many processes such as addition and substitution reactions.

Abstract: The present invention relates to charge transport compositions. The invention further relates to electronic devices in which there is at least one active layer comprising such charge transport compositions.

Abstract: The invention relates to fluorescent dyes. More particularly, the invention relates to fluorescent cyanine dyes, and especially to water soluble fluorescent cyanine dyes that contain additional sites for attachment to biomolecules. The invention provides a group of novel, water soluble fluorescent cyanine dyes that have distinct fluorescence characteristics that permit their use in any assay or method suited to water soluble fluorescent dyes, and especially to assays requiring a plurality of distinguishable fluorescent markers. The invention further relates to nucleotides, nucleosides, polynucleotides and polypeptides labeled with novel fluorescent cyanine dyes according to the invention, and methods of using them.

Abstract: Non-steroidal compounds and compositions which are agonists, partial agonists, and antagonists for androgen receptors and methods of preparation for the non-steroidal compounds and compositions.

Abstract: The present invention discloses novel sulfenate derivatives and their bioconjugates for phototherapy of tumors and other lesions. The sulfenates of the present invention are designed to absorb low-energy ultraviolet, visible, or near-infrared (NIR) region of the electromagnetic spectrum. The phototherapeutic effect is caused by direct interaction of free radicals, the reactive intermediate produced upon photofragmentation of the sulfenate moiety, with the tissue of interest.

Abstract: A pharmaceutical composition comprising an efficient amount of a compound selected among the compounds of formulae (I) and (II). The compounds have useful cytotoxic properties providing therapeutic application as antitumoral medicine.

Abstract: Sensing elements, sensor systems and methods for determining the concentration of oxygen and oxygen-related analytes in a medium are provided. The sensing element comprises a solid polymeric matrix material that is permeable to oxygen or an oxygen related analyte and an indicator that is covalently bonded to the solid polymeric matrix material. The indicator is a luminescent platinum group metal polyaromatic chelate complex capable of having its luminescence quenched by the presence of oxygen The polyaromatic complex comprises three ligands, at least one of which is a bidentate diphenylphenanthroline. The polyaromatic complex is distributed substantially homogenously throughout the matrix material and is covalently bonded to the matrix material via a linker arm. The linker arm is attached to a phenyl group of a diphenylphenanthroline ligand and to the backbone of the polymeric matrix material.

Abstract: Benzo[f]naphthyridine derivatives of formula (I): benzo[f]naphthyridine derivatives and benzo[f]naphthyridine esters of formula (IVa): aminoquinoline derivatives of formula (X): processes for preparing such compounds; and compositions comprising them.

Abstract: The invention relates to 1,10 phenanthroline derivatives substituted at the 3-,8-positions.

Abstract: Bis-o-aminophenols and o-aminophenolcarboxylic acids have the following structures: A1 to A7 are, independently of each other, H, F, CH3, CF3, OCH3 or OCF3. T is an aromatic or heterocyclic residue. A method for preparing bis-o-aminophenols and o-aminophenolcarboxylic acids is also provided.

Abstract: Bipyridine or phenanthroline ligands presenting functional groups that prevent non-specific binding (in particular, negatively charged functional groups that are unaffected by standard conditions for conjugating biological reagents through amide bonds) are described as are luminescent metal complexes comprising these ligands. The use of luminescent ruthenium and osmium complexes comprising these ligands in electrochemiluminescence assays shows that the use of these labels can significantly reduce the amount of non-specific binding observed relative to assays carried out using reagents labeled with analogous labels that don't present functional groups that decrease non-specific binding.

Abstract: Pharmaceutical compounds comprising bridged nicotine analogs of N-octylnicotinium iodide (NONI) having selective antagonist properties at &agr;3&bgr;2-containing nicotinic receptor subtypes, and compositions containing these compounds. The compounds and compositions are used to treat central nervous system pathologies.

Abstract: The invention provides methods for treating cancer and vanadium compounds that are useful for the treatment of tumors, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates useful for preparing the compounds.

Abstract: A novel naphthyridine derivative showing high activity as a tachykinin receptor antagonist can be produced at high efficiency by reacting an acylating agent such as a carboxylic acid derivative with a compound represented by the formula (1): wherein R1, R2 and R3 represent independently a hydrogen atom, a lower alkyl group, a lower alkoxyl group, an aryl group, a heteroaryl group, an amino group, etc., and X1 and X2 represent respectively a halogen atom.

Abstract: The present invention provides a phenanthroline derivative of formula (I) 1

Abstract: The present invention provides a phenanthroline derivative of formula (I) wherein, for example, R1 is hydrogen, carboxy, cyano, nitro, (1-4C)alkyl, (1-6C)alkoxycarbonyl, (1-4C)alkylamino, (2-4C)alkanoyl, (1-4C)alkoxy-(2-4C)alkoxy-(2-4C)alkoxycarbonyl or N-[amino-(2-8C)alkyl]carbamoyl; R2 is, for example, hydrogen, carboxy, (1-6C)alkoxycarbonyl, carbamoyl, N-(1-8C)alkylcarbamoyl, N,N-di-(1-8C)alkylcarbamoyl, N-(1-4C)alkylcyclohexylcarbamoyl, 1,2,3,4-tetrahydro-isoquinolin-2-ylcarbonyl or N,N-[di-(1-4C)alkyl]thiocarbamoyl; R3 and R4, which may be the same or different, are, for example, hydrogen or halo; and R5 is, for example, hydrogen, di-(1-4C)alkylamino or halo; or a pharmaceutically-acceptable salt thereof. The invention further provides pharmaceutical compositions comprising phenanthroline derivatives, processes for making the same and their use in producing an anti-fibroproliferative effect.

Abstract: Disclosed are nitrosated and/or nitrosylated phosphodiesterase inhibitors having the formula NOn-PDE inhibitor where n is 1 or 2. The invention also provides compositions comprising such compounds in a pharmaceutically acceptable carrier. The invention also provides a composition comprising a therapeutically effective amount of an phosphodiesterase inhibitor (PDE inhibitor), which can optionally be substituted with at least one NO or NO2 moiety, and one to ten fold molar excess of a compound that donates, transfers or releases nitrogen monoxide as a charged species, i. e., nitrosonium (NO+) or nitroxyl (NO−), or as the neutral species, nitric oxide (NO.) or which stimulates endogenous EDRF production. The invention also provides compositions comprising such compounds in a pharmaceutically acceptable carrier. The invention also provides methods for treating sexual dysfunctions in males and females.

Abstract: Fluorinated phenanthrene derivatives and their use in liquid-crystalline mixtures Fluorinated phenanthrene derivatives of the formula (I) in which G is —CHF—CH2— or —CF═CH—, E1, E2, E3, E4, E5 and E6 are identical or different and are —CH—, —CF— or —N— and R1(—A1—M1)a(—A2—M2)b, (M3—A3—)c(M4—A4—)d R2 denote mesogenic radicals are suitable as components for liquid-crystalline mixtures, especially ferroelectric mixtures.

Abstract: Duplex polynucleotides containing damage or errors are detected with hindered intercalating compounds which are capable of intercalating only in the presence of such damage or error. Conditions characterized by the presence of polynucleotide errors or damage are treated with such compounds that are capable of catalyzing polynucleotide cleavage with light. Suitable compound include compounds of the formula:Rh(R.sub.1)(R.sub.2)(R.sub.3).sup.3+where R.sub.1 and R.sub.2 are each independently aryl, heteroaryl, substituted aryl or substituted heteroaryl of 1 to 5 rings, and R.sub.3 is a group of the formula ##STR1## where x and z are each independently an integer from 1 to 4 and y is an integer from 1 to 2, and R.sub.4, R.sub.5, and R.sub.6 are each independently H--, halo, HO--, H.sub.2 N--, CN--, O.sub.2 N--, HS--, O.sub.3 S--, O.sub.3 SO--, --COOH, --CONH.sub.2, R, RO--, RNH--, R.sub.a R.sub.b N--, RO.sub.3 S--, RO.sub.3 SO--, --COOR, --CONHR, or --CONR.sub.a R.sub.b, where R, R.sub.a and R.sub.

Abstract: The present invention provides a phenanthroline derivative of formula (I) ##STR1## wherein, for example, R.sup.1 is hydrogen, carboxy, cyano, nitro, (1-4C)alkyl, (1-6C)alkoxycarbonyl, (1-4C)alkylamino, (2-4C)alkanoyl, (1-4C)alkoxy-(2-4C)alkoxy-(2-4C)alkoxycarbonyl or N-?amino-(2-8C)alkyl!carbamoyl;R.sup.2 is, for example, hydrogen, carboxy, (1-6C)alkoxycarbonyl, carbamoyl, N-(1-8C)alkylcarbamoyl, N,N-di-(1-8C)alkylcarbamoyl, N-(1-4C)alkylcyclohexylcarbamoyl, 1,2,3,4-tetrahydro-isoquinolin-2-ylcarbonyl or N,N-?di-(1-4C)alkyl!thiocarbamoyl;R.sup.3 and R.sup.4, which may be the same or different, are, for example, hydrogen or halo; andR.sup.5 is, for example, hydrogen, di-(1-4C)alkylamino or halo; or a pharmaceutically-acceptable salt thereof.The invention further provides pharmaceutical compositions comprising phenanthroline derivatives, processes for making the same and their use in producing an anti-fibroproliferative effect.

Abstract: Compound of formula (I): ##STR1## in which: m, n, which are identical or different, represent 0, 1 or 2,R.sub.1, R.sub.2, which are identical or different, represent hydrogen, optionally substituted alkyl, aryl, or form with the carbon atom carrying them carbonyl or (C.sub.3 -C.sub.7)cycloalkyl,R.sub.3 represents hydrogen, alkyl, hydroxyl or aryl,R.sub.4 represents any of the groups as defined in the description,X represents --SO.sub.2 --, --CO-- or --SO.sub.2 NH--,R.sub.5 represents optionally substituted alkyl, (C.sub.3 -C.sub.7)cycloalkyl, aryl or heterocyclic,A represents an aryl ring or a heterocycle,its isomers as well as its addition salts with a pharmaceutically acceptable acid or base and medicinal products containing the same are useful as metalloprotease inhibitors.

Abstract: This invention relates to methods, reagents, and kits utilizing metal chelates to inactivate nucleotide sequences, especially to inactivate polymerase chain reaction (PCR) and ligase chain reaction (LCR) products and to inactivate nucleotide sequences in a bioprocess and bioproduct. A novel metal chelate class is also disclosed.